toborinone

05/01/1998 - "Intracoronary administration of OPC-18790 demonstrates that the direct myocardial effects of this agent include a modest increase in inotropy and improvement in diastolic function, both of which occur without increases in heart rate, indicating that this agent may be beneficial for the intravenous treatment of congestive heart failure."
06/01/1999 - "Continuous infusion of toborinone appears to be effective for treating heart failure occurring immediately after ECC in cardiac surgery. "
01/01/1997 - "Thus toborinone, a positive inotropic agent without chronotropic action, may be effective in acute treatment of ischemic heart failure."
12/01/1996 - "These results suggest that toborinone may be useful for the management of chronic and congestive heart failure."
08/01/1996 - "Our findings suggest that OPC-18790 may be useful for the treatment of patients with congestive heart failure."

02/01/1996 - "We studied the contribution and relative dose sensitivities of the inotropic, lusitropic, and vascular effects of OPC-18790 in patients with dilated cardiomyopathy. "
02/01/1997 - "Effect of dobutamine and OPC-18790 on diastolic chamber stiffness in patients with idiopathic dilated cardiomyopathy."
02/01/1997 - "We investigated the acute effects of the positive inotropic agents (dobutamine and a novel phosphodiesterase inhibitor OPC-18790) on left ventricular diastolic chamber stiffness in patients with idiopathic dilated cardiomyopathy (DCM). "

10/01/1994 - "At infusion rates yielding comparable increases in the cardiac index (5 micrograms/kg/min for 2 hours for each drug), OPC-18790 produced significantly more favorable effects on heart rate (-2 +/- 3% vs 11 +/- 4%; P = .01), pulmonary capillary wedge pressure (-32 +/- 4% vs -17 +/- 8%; P = .04), mean pulmonary arterial pressure (-14 +/- 3% vs 6 +/- 11%; P = .06), stroke volume index (48 +/- 8% vs 29 +/- 7%; P = .02), stroke work index (70 +/- 11 vs 42% +/- 12%; P = .03), and rate pressure product (2 +/- 4% vs 14 +/- 4%; P = .05). "

11/01/1995 - "Arrhythmias such as premature ventricular contraction developed in 5 out of 7 dogs (71.4%) in the 10-micrograms/kg/min dopamine group, while only one premature ventricular contraction was observed in 1 of 7 dogs (14.3%) in the OPC-18790 (10 micrograms/kg/min) and dopamine (5 micrograms/kg/min) combination group. "

11/01/1993 - "We also examined the effects of OPC-18790 on ventricular arrhythmias in canine ventricular tachycardia (VT) models. "